BlueWillow Biologics has developed a proprietary intranasal adjuvant technology that utilizes a unique oil-in-water nanoemulsion platform. This platform features emulsion droplets approximately 400 nanometers in size, which are designed to incorporate various antigens, including recombinant proteins and polysaccharides. The technology not only facilitates the effective delivery of antigens directly to antigen-presenting cells but also ensures a strong safety profile, as it prevents the crossing of the blood-brain barrier. This characteristic, combined with the platform's ability to elicit a balanced immune response, positions it as a leading solution for intranasal vaccine development. The immune response generated is predominantly Th1-biased, promoting durable cell-mediated immunity while also triggering systemic responses, such as the production of IgG and IgA antibodies.

The versatility of BlueWillow's adjuvant technology extends beyond traditional vaccination, as it also shows promise in immunotherapy applications, particularly for food allergies. The platform's compatibility with a wide range of antigens and its inherent antiviral properties enable the formulation of whole inactivated virus vaccines. By addressing the limitations of non-adjuvanted intranasal vaccination approaches, BlueWillow's technology aims to provide robust protection against mucosal respiratory and sexually transmitted pathogens, thereby enhancing the efficacy and safety of future vaccine candidates.

United States

BlueWillow Biologics® is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. Our novel intranasal NanoVax® adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including Peanut Allergy, HSV-2, Covid-19, Anthrax, Pandemic Flu and RSV.

BlueWillow Biologics

Company Details